New PBM law could lead to direct sales between employers, drugmakersNew PBM law could open door to direct sales between employers, drugmakers

The recent pharmacy benefit manager reforms signed into law by President Trump have the potential to revolutionize the way employers purchase drugs for their employees. The reforms, included in a Health and Human Services spending bill passed by Congress, aim to increase transparency and accountability in the pharmaceutical industry.

One significant change brought about by the new law is the prohibition of PBMs from linking their payments to drug prices in Medicare. Additionally, in the commercial market, PBMs are now required to pass through 100% of rebates to employer-sponsored insurance plans. These measures are designed to make drug pricing more transparent and to ensure that employers are getting the best value for their money.

The reforms have sparked debate within the industry, with the Pharmaceutical Care Management Association expressing concerns that the new restrictions could lead to higher prices by restricting the negotiation of drug rebates. However, proponents of the reforms argue that increased transparency will ultimately benefit employers and consumers by allowing them to make more informed decisions about their healthcare spending.

One potential outcome of the reforms is that employers may start buying drugs directly from drugmakers, bypassing PBMs altogether. In the past, some large employers have considered this option as a way to avoid the higher list prices associated with PBMs. With the new disclosure requirements in place, drugmakers may be more willing to work with employers directly, leading to more creative arrangements in the industry.

The new law also requires PBMs to provide detailed reports to plan sponsors, including information on drug spending, rebates, and fees paid to third parties. This increased transparency will help employers better understand how their healthcare dollars are being spent and make more informed decisions about their drug benefit plans.

In addition to the PBM reforms, the bill includes new transparency requirements for hospital billing, additional support for pediatric cancer research, and Medicare coverage of multi-cancer screening tests. These measures are aimed at improving healthcare access and affordability for all Americans.

Overall, the pharmacy benefit manager reforms represent a significant step towards greater transparency and accountability in the pharmaceutical industry. By empowering employers to make more informed decisions about their drug benefit plans, the reforms have the potential to drive down costs and improve access to essential medications for millions of Americans.